drugset
drugset / Trial / NCT02016365

Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis

NCT02016365 ↗

Phase 2 Completed 55 enrolled Umeå University
NaSingle-groupOpen-labelTreatment

Summary

The primary objective for this study is to evaluate the efficacy of doxycycline + ursodeoxycholic acid (UDCA) on disease progression in Transthyretin Amyloidosis (ATTR) subjects with cardiomyopathy with or without neuropathy.

Timeline

Start
2012-02
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 100 mg Oral
Subject Ursodeoxycholic Acid Small molecule 750 mg Oral

Indications

cardiomyopathy